These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 9218984)

  • 21. [Modern therapy for dementia].
    Padberg F; Möller HJ; Bottlender R; Hampel H
    MMW Fortschr Med; 2005 May; 147 Spec No 2():71-4, 76-7. PubMed ID: 15968877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. length of clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Levy R
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():33. PubMed ID: 9305513
    [No Abstract]   [Full Text] [Related]  

  • 23. [Dementing disorders. What benefits do the new anti-dementia drugs have?].
    Ihl R
    MMW Fortschr Med; 2002 May; Suppl 2():24-6, 28-9. PubMed ID: 12070846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dementia.
    Warner J; Butler R; Jackson E
    Clin Evid; 2002 Dec; (8):927-50. PubMed ID: 12603921
    [No Abstract]   [Full Text] [Related]  

  • 25. Neuropsychiatric outcome for clinical trials.
    Robert P; Verhey FR; Aalten P; Cortes F; Byrne EJ
    J Nutr Health Aging; 2007; 11(4):345-7. PubMed ID: 17653496
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment for Alzheimer's disease.
    Wilcock GK
    Int J Geriatr Psychiatry; 2000 Jun; 15(6):562-5. PubMed ID: 10861924
    [No Abstract]   [Full Text] [Related]  

  • 27. Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Gauthier S; Bodick N; Erzigkeit E; Feldman H; Geldmacher DS; Huff J; Mohs R; Orgogozo JM; Rogers S
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():6-7. PubMed ID: 9305507
    [No Abstract]   [Full Text] [Related]  

  • 28. Cognitive issues in Parkinson's disease.
    Elmer L
    Neurol Clin; 2004 Oct; 22(3 Suppl):S91-S106. PubMed ID: 15501368
    [No Abstract]   [Full Text] [Related]  

  • 29. Nicergoline: parallel evolution of clinical trial methodology and drug development in dementias.
    Crook TH
    Dement Geriatr Cogn Disord; 1997; 8 Suppl 1():22-6. PubMed ID: 9205835
    [No Abstract]   [Full Text] [Related]  

  • 30. Drugs for cognitive loss and dementia.
    Med Lett Drugs Ther; 2017 Sep; 59(1530):155-161. PubMed ID: 28922342
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical inquiries. Does treatment with donepezil improve memory for patients with mild cognitive impairment?
    Stiles MM; Martin S; Persons RK
    J Fam Pract; 2006 May; 55(5):435-6. PubMed ID: 16670040
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical trials of treatment for noncognitive symptoms of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Homma A; Brodaty H; Bruno G; Cummings JL; Gilman S; Gracon S; McKeith IG
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():54-5. PubMed ID: 9305518
    [No Abstract]   [Full Text] [Related]  

  • 33. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia.
    Aarsland D; Hutchinson M; Larsen JP
    Int J Geriatr Psychiatry; 2003 Oct; 18(10):937-41. PubMed ID: 14533126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antipsychotics and cognitive function.
    Azumi M; Ishizuka S; Fujii M; Sasaki H
    Psychogeriatrics; 2011 Jun; 11(2):79-82. PubMed ID: 21707854
    [No Abstract]   [Full Text] [Related]  

  • 35. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis.
    Harry RD; Zakzanis KK
    Hum Psychopharmacol; 2005 Apr; 20(3):183-7. PubMed ID: 15700322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapy approaches in cerebral cognitive deficits--neuropsychiatric aspects].
    Reisecker F
    Wien Med Wochenschr; 1996; 146(21-22):546-8. PubMed ID: 9092214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Reisberg B; Schneider L; Doody R; Anand R; Feldman H; Haraguchi H; Kumar R; Lucca U; Mangone CA; Mohr E; Morris JC; Rogers S; Sawada T
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():8-18. PubMed ID: 9305508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?
    Vellas B; Andrieu S; Cantet C; Dartigues JF; Gauthier S
    J Nutr Health Aging; 2007; 11(4):338-41. PubMed ID: 17653494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognition-enhancing drugs in dementia: a guide to the near future.
    van Reekum R; Black SE; Conn D; Clarke D
    Can J Psychiatry; 1997 Jun; 42 Suppl 1():35S-50S. PubMed ID: 9220128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison table: drugs for Alzheimer's disease.
    Med Lett Drugs Ther; 2017 Sep; 59(1530):e160-e161. PubMed ID: 28922344
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.